#PierreFabre #ECapproval #Braftovi #encorafenib #colorectalcancer #BRAFV600EmutantmCRC #metastaticcolorectalcancer #mCRC #combinationtherapy #cetuximab #FOLFOX #phase3 #Breakwatertrial #progressionfreesurvival #primaryendpoint #overallsurvivalbenefit #LaboratoiresPierreFabre
zurl.co/7jFHW
zurl.co/7jFHW
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC - PharmaTimes
Breakwater phase 3 data show significant gains in progression‑free survival
pharmatimes.com
June 24, 2026 at 8:48 AM
🔗 Read more: bit.ly/ONCOnews25N-1
#ONCOnews #OncoAlert #OncEd #OncologyNews #ECApproval #CancerTreatment
#ONCOnews #OncoAlert #OncEd #OncologyNews #ECApproval #CancerTreatment
November 25, 2025 at 10:30 AM